ウェビナー動画：Ferring Pharmaceuticals社、創薬初期バイオ医薬品スクリーニングにおける生物物理データに基づく開発適性評価

生物物理学的特性評価は、豊富なデータを生み出します。このような生物物理学的特性評価においては、それらデータが構造化され、相互につながり、意思決定に活用できる状態になっているかが重要です。本講演では、Genedata Screener^®を用いた生物物理データに基づく開発適性評価が実際の創薬プロセスにおいてどのように行われているかを紹介しています。

Successful biotherapeutic development requires optimizing multiple properties (such as thermal stability, aggregation risk, and expression efficiency) measured across diverse assay technologies. Integrating these data for candidate selection can be challenging, especially in early developability studies where assays are run at higher throughput.  

This webinar will explore the use of Genedata Screener in evaluating biophysical developability data, specifically focusing on dynamic light scattering (DLS) and differential scanning fluorimetry (DSF) (in particular, its label-free version, nanoDSF).  

Learn how these methods are incorporated into early screening workflows for biologics at Ferring Pharmaceuticals A/S, enabling highly efficient and reliable assessment of molecular properties.  

The session covers practical approaches for analyzing and interpreting biophysical data, with real-world examples to demonstrate how Genedata Screener streamlines the candidate profiling process and supports consistent, well-informed decision making in drug development.